Pharmafile Logo

Laminar Medica Ltd

Laminar Medica specialises in the design, test, manufacture and qualification of insulated shipping systems, used by the pharmaceutical and biotech industries globally. These systems protect vaccines, drugs, blood and associated medical products from extremes of temperature during transportation.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

Unit 4, Tring Industrial Estate Icknield Way, Tring, Hertfordshire, HP23 4JX, United Kingdom
+44 (0)1442 828664

 Latest Content from PMHub 

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Infographic: Spondyloarthritis

Overview of spondyloarthritis patient profiles and treatment pathways.

Webinar: Demand assessment – Reflecting real world choices

How study design which reflects doctors’ real world choices can optimise results.

Evaluating the potential of a pre-launch prodct in a real-life setting

Using in-depth-interviews as well as a SmartPhone app to collect real patient cases from physicians to find out opportunity for a new product.

Blue Latitude Health shortlisted for two PMEA 2015 awards

Blue Latitude Health’s Medical Information Cascade project for Eli Lilly and Company has been shortlisted in the Excellence in Physicians/Healthcare Provider Support Programmes and Innovation categories.

10 tips for developing insightful pre-launch positioning

By getting your positioning right, you can build the motivational, aspirational, and resonant brand story and messaging that will allow your product to become a brand. Blue Latitude Health's Head...

Bigger than brand: Portfolio Positioning for Pharma

Senior Consultant Jenna Earl talks us through the three most important things to understand about portfolio positioning in pharma.

Tackling biosimilars – how to handle the threat to Pharma brands

Strategy Consultant Mark Assenti outlines three key points for developing a strategy to tackle the threat to Pharma brands from biosimilars.